[go: up one dir, main page]

NO20075304L - Metode for avtagende forkalkning - Google Patents

Metode for avtagende forkalkning

Info

Publication number
NO20075304L
NO20075304L NO20075304A NO20075304A NO20075304L NO 20075304 L NO20075304 L NO 20075304L NO 20075304 A NO20075304 A NO 20075304A NO 20075304 A NO20075304 A NO 20075304A NO 20075304 L NO20075304 L NO 20075304L
Authority
NO
Norway
Prior art keywords
calcification
decreasing
emimetics
individuals
calcium
Prior art date
Application number
NO20075304A
Other languages
English (en)
Inventor
David Martin
Juan Mariano Portillo
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20075304L publication Critical patent/NO20075304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen angår fremgangsmåter for å behandle vaskulær forkalkning i individer ved å bruke kalsimimetika.
NO20075304A 2005-03-17 2007-10-17 Metode for avtagende forkalkning NO20075304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66327005P 2005-03-17 2005-03-17
PCT/US2006/009683 WO2006102061A2 (en) 2005-03-17 2006-03-17 Methods of decreasing calcification

Publications (1)

Publication Number Publication Date
NO20075304L true NO20075304L (no) 2007-11-29

Family

ID=36588866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075304A NO20075304L (no) 2005-03-17 2007-10-17 Metode for avtagende forkalkning

Country Status (15)

Country Link
US (1) US20060276534A1 (no)
EP (1) EP1858553A2 (no)
JP (1) JP2008533170A (no)
KR (1) KR20070116817A (no)
CN (1) CN101184508A (no)
AU (1) AU2006227429A1 (no)
BR (1) BRPI0609524A2 (no)
CA (1) CA2601669A1 (no)
CR (1) CR9439A (no)
EA (1) EA200701995A1 (no)
IL (1) IL185757A0 (no)
MX (1) MX2007011153A (no)
NO (1) NO20075304L (no)
WO (1) WO2006102061A2 (no)
ZA (1) ZA200707639B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127941A2 (en) * 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Amorphous cinacalcet hydrochloride and preparation thereof
JP2009512710A (ja) * 2005-10-21 2009-03-26 アムジエン・インコーポレーテツド Ｉｌ−１阻害剤を用いて血管石灰化を抑制する方法
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
KR20080055990A (ko) * 2005-11-22 2008-06-19 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
EP2001832A1 (en) * 2006-03-23 2008-12-17 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
US8779004B2 (en) * 2006-04-20 2014-07-15 Amgen, Inc. Stable emulsion formulations
US7449603B2 (en) * 2006-04-27 2008-11-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
EP1928817A1 (en) * 2006-04-27 2008-06-11 Teva Pharmaceutical Industries Ltd Process for the preparation of cinacalcet base
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
JP5671336B2 (ja) * 2007-05-08 2015-02-18 バーナム インスティテュート フォー メディカル リサーチ 組織非特異的アルカリホスファターゼ阻害因子および血管石灰化を処置するためのそれらの使用
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
MX355063B (es) * 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
MX2020011742A (es) * 2018-10-25 2021-02-15 Eirgen Pharma Ltd Métodos de tratamiento con compuestos metálicos mixtos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP1275635A1 (en) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
DE69739388D1 (de) * 1996-05-01 2009-06-10 Nps Pharma Inc Inorganische am Ionen-Rezeptor aktive Verbindungen
US6362231B1 (en) * 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
JP2002527414A (ja) * 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド １，２−ジ置換シクロプロパン
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
DE60017285T2 (de) * 1999-10-19 2005-12-08 Genzyme Corp., Cambridge Direktkomprimierter tablettenkern auf polymerbasis
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US20050288377A1 (en) * 2004-06-14 2005-12-29 Cantor Thomas L Use of calcimimetic as an adynamic bone disease related treatment

Also Published As

Publication number Publication date
MX2007011153A (es) 2007-12-12
ZA200707639B (en) 2008-06-25
US20060276534A1 (en) 2006-12-07
KR20070116817A (ko) 2007-12-11
BRPI0609524A2 (pt) 2011-10-18
EA200701995A1 (ru) 2008-02-28
WO2006102061A3 (en) 2006-12-14
EP1858553A2 (en) 2007-11-28
CR9439A (es) 2007-11-23
CN101184508A (zh) 2008-05-21
JP2008533170A (ja) 2008-08-21
IL185757A0 (en) 2008-01-06
AU2006227429A1 (en) 2006-09-28
WO2006102061A2 (en) 2006-09-28
CA2601669A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
NO20075304L (no) Metode for avtagende forkalkning
WO2007092622A3 (en) Compositions and methods for treating bone
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
WO2007120626A3 (en) Uses and compositions for treatment of ankylosing spondylitis
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
NO20092637L (no) Fremgangsmater for behandling
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EP2373692A4 (en) IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
NO20071378L (no) Tiazolo-naftylsyrer.
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application